HQ Team
January 30, 2023: PathLabs Unifiers, a subsidiary of diagnostic services company Dr. Lal PathLabs, has acquired a 10% stake in one of its business units, APRL PathLabs, in INR 7.5 million in cash.
APRL PathLabs recorded a turnover of INR 19.79 million in the year ended March 31, 2020, INR 86.98 million in 2021 and INR 107.96 million in 2022.
According to a BSE filing, the acquisition of shares will strengthen the company’s presence in the western state of Gujarat, India.
The additional shares will be brought within the next three months in cash valued at about INR. 7.50 million, and the total equity stake of Path Unifiers will increase to 80% post-acquisition.
Gujarat state
APRL PathLabs was incorporated on October 4, 2019, in Gujarat state and is engaged in providing diagnostic services.
Dr. Lal PathLabs has an integrated nationwide network with a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and prevention.
It also has tests to monitor and treat disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates.
The list of services includes 491 test panels, 2,675 pathology tests and 1,947 radiology and cardiology tests as on March 31, 2022. The company, 55.2% owned by promoter and promoter groups, has 277 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 4,731 Patient Service Centers and 10,599 pick-up-points.
49.7 million samples
In FY21 & FY22, DLPL collected and processed approximately 49.7 million samples and 66 million samples from about 20.3 million and 27.3 million patients, respectively.
In the Q4 of 2022 revenue of the company rose 12.7% to INR 4,855 million from INR 4,310 million.
